Possible Option for Treatment of Severe Congestive Heart Failure Under Mechanical Ventilation Using Tolvaptan via Nasogastric Tube: A Single-Center Analysis

1. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151-2159. doi: 10.1016/j.jacc.2007.01.091.10.1016/j.jacc.2007.01.09117543634Search in Google Scholar

2. Konstam MA, Gheorghiade M, Burnett JCJ, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-1331. doi: 10.1001/jama.297.12.1319.10.1001/jama.297.12.131917384437Search in Google Scholar

3. Tavare AN, Murray D. Central pontine myelinolysis. N Engl J Med. 2016;374:e8. doi: 10.1056/NEJMicm1504134.10.1056/NEJMicm150413426886548Search in Google Scholar

4. Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10:188-195. doi: 10.1016/j.ejheart.2008.01.011.10.1016/j.ejheart.2008.01.01118279773Search in Google Scholar

5. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980-988. doi: 10.1093/eurheartj/ehl542.10.1093/eurheartj/ehl54217309900Search in Google Scholar

6. Takeda M, Takada T, Satake H, Sugeno M, Kanemitsu H, Shiba N. Efficacy and safety of tolvaptan administration from nasogastric tube in patients under mechanical ventilation with severe congestive heart failure [in Japanese]. Shinzo. 2016;48:1033-1041. doi: 10.11281/shinzo.48.1033.Search in Google Scholar

7. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med. 1971;285:1441-1446. doi: 10.1056/NEJM197112232852601.10.1056/NEJM1971122328526015122894Search in Google Scholar

8. JCS Joint Working Group. Guidelines for treatment of acute heart failure (JCS 2011). Circ J. 2013;77:2157–2201. doi: 10.1253/circj.cj-66-0068.10.1253/circj.CJ-66-0068Search in Google Scholar

9. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.Search in Google Scholar

10. Matsue Y, Suzuki M, Torii S, et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail. 2016;22:423-432. doi: 10.1016/j. cardfail.2016.02.007.Search in Google Scholar

11. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696. doi: 10.1161/01. CIR.0000070422.41439.04.Search in Google Scholar

12. Kinugawa K, Sato N, Inomata T, Yasuda M, Shimakawa T, Fukuta Y. Real-world effectiveness and tolerability of tolvaptan in patients with heart failure – final results of the Samsca post-Marketing surveillance In heart faiLurE (SMILE) Study. Circ J. 2019;83:1520-1527. doi: 10.1253/circj.CJ-19-0158.10.1253/circj.CJ-19-015831118355Search in Google Scholar

13. Darmon M, Timsit JF, Francais A, et al. Association between hypernatraemia acquired in the ICU and mortality: a cohort study. Nephrol Dial Transplant. 2010;25:2510-2515. doi: 10.1093/ndt/gfq067.10.1093/ndt/gfq06720167570Search in Google Scholar

14. Abdel-Qadir HM, Tu J V, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J. 2010;160:264-271. doi: 10.1016/j.ahj.2010.05.032.10.1016/j.ahj.2010.05.03220691831Search in Google Scholar

15. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-1764. doi: 10.1016/j.amjcard.2005.12.072.10.1016/j.amjcard.2005.12.07216765130Search in Google Scholar

16. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-338. doi: 10.1016/j.ahj.2003.08.012.10.1016/j.ahj.2003.08.01214760333Search in Google Scholar

17. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805. doi: 10.1056/NEJMoa1005419.10.1056/NEJMoa1005419341235621366472Search in Google Scholar

18. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729. doi: 10.1161/01.cir.82.5.1724.10.1161/01.CIR.82.5.17242146040Search in Google Scholar

19. Nakada Y, Takahama H, Kanzaki H, et al. The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure. Heart Vessels. 2016;31:925-931. doi: 10.1007/s00380-015-0688-7.10.1007/s00380-015-0688-725964073Search in Google Scholar

20. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-278. doi: 10.1152/ajprenal.00195.2005.10.1152/ajprenal.00195.2005264714016189291Search in Google Scholar

21. Matsukawa R, Kubota T, Okabe M, Yamamoto Y. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels. 2016;31:1650-1658. doi: 10.1007/s00380-015-0780-z.10.1007/s00380-015-0780-z26676672Search in Google Scholar

22. Kimura K, Momose T, Hasegawa T, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol. 2016;67:399-405. doi: 10.1016/j.jjcc.2015.09.020.10.1016/j.jjcc.2015.09.02026692119Search in Google Scholar

23. Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST Study). Cardiovasc Drugs Ther. 2011;25:S33-S45. doi: 10.1007/s10557-011-6304-x.10.1007/s10557-011-6304-x22120092Search in Google Scholar

24. Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment – results from the K-STAR study. Circ J. 2017;82:159-167. doi: 10.1253/circj.CJ-17-0179.10.1253/circj.CJ-17-017928835586Search in Google Scholar